Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Novo Nordisk Thailand has announced the successful implementation of a blockchain-based traceability solution to verify the authenticity of Ozempic® across the supply chain, addressing the growing ...

Novo Nordisk is planning ... a new generation of medicinal products. In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery ...

Novo Nordisk A/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products ... Jr. to head the Department of Health and Human Services and ...

The Weight Loss Drugs Market is poised for significant growth from 2025 to 2035. With increasing obesity rates, rising ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... as well as the EDOC Telemedicine and Digital Health ETF. We then ranked these stocks based on the number of ...

With rising global demand for more personalised and effective healthcare solutions, the Department of Health - Abu Dhabi (DoH ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma ... advertising its products as "healthy." ...

to support the marketing of Novo Nordisk products to US diabetes patients. "...the online environment is arguably saturated with content relating to the disease." The Cornerstones4Care website ...

London: The Novo ... products, represented a potential conflict of interest. They also noted links between some of the people involved in the project and the food industry. The Novo Nordisk ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...